NCT03761225 2023-09-29
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
AB Science
Phase 3 Completed
Clinical Trials
12 trialsNCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed
NCT02490488 2020-12-08
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
AB Science
Phase 2/3 Completed
NCT03556956 2020-12-08
Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer
AB Science
Phase 2/3 Completed
NCT03766295 2020-12-08
Masitinib Plus Gemcitabine in Pancreatic Cancer
AB Science
Phase 3 Completed
NCT00814073 2019-12-03
AB06006
AB Science
Phase 3 Completed
NCT00866138 2019-12-03
Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3
AB Science
Phase 2 Completed
NCT00789633 2018-12-17
Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
AB Science
Phase 3 Completed
NCT00831974 2018-12-11
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
AB Science
Phase 2 Completed
NCT00998751 2018-12-11
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
AB Science
Phase 2 Completed
NCT01506336 2018-12-11
Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
AB Science
Phase 2 Completed
NCT01266369 2018-12-10
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
AB Science
Phase 2 Completed